Source comparison
What evidence supports cyclical versus continuous tesamorelin use?
Tesamorelin is usually run as a defined block rather than open-ended continuous use. A common peptide-user structure is 8–16 weeks on, then a 2–4 week break or reassessment, with IGF-1 and glucose markers guiding the next step. The reason is not a formal withd
This comparison does not assign a generated winner or score.
- Tesamorelin is usually run as a defined block rather than open-ended continuous use. A common peptide-user structure is 8–16 weeks on, then a 2–4 week break or reassessment, with IGF-1 and glucose markers guiding the next step. The reason is not a formal withdrawal requirement; it is risk management for sustained IGF-1 elevation, edema, glucose drift, and loss of a clean pulse pattern. Longer use belongs in a clinician-managed plan with labs, not an automatic forever protocol.